Tag Archives: CHMP

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer – Merck.com

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer  Merck.com FDA OKs New Keytruda Shot for Cancer  The New York Times Pembrolizumab Earns 2 Positive CHMP Opinions in HNSCC, Other EU Indications  OncLive Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial …

Read More »

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2025

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2025

13 new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended 13 medicines for approval at its July 2025 meeting. The committee recommended granting a marketing authorisation for Aqneursa* (levacetylleucine), for the treatment of Niemann-Pick type C, a rare, progressive, fatal genetic disorder caused by mutations encoding lysosomal proteins that are essential for the intracellular transport and metabolism of …

Read More »